Patent classifications
C07D251/18
CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME
A cyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same, and the compound used as a material of an organic material layer in the organic light emitting device and providing improved efficiency, low driving voltage and improved lifetime characteristics of the organic light emitting device.
##STR00001##
Compounds and compositions for ossification and methods related thereto
The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Compounds and compositions for ossification and methods related thereto
The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Guanidine compounds and use thereof
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
Guanidine compounds and use thereof
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE
The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R.sup.1a, R.sup.2a, R.sup.3a, A.sup.1, A.sup.2, A.sup.3, R.sup.1b, R.sup.2b, R.sup.3b, B.sup.1, and B.sup.2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and α-synucleinopathies, such as Parkinson's disease.
##STR00001##
HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE
The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R.sup.1a, R.sup.2a, R.sup.3a, A.sup.1, A.sup.2, A.sup.3, R.sup.1b, R.sup.2b, R.sup.3b, B.sup.1, and B.sup.2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and α-synucleinopathies, such as Parkinson's disease.
##STR00001##
SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
Compounds of the general formula):
##STR00001##
processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, and/or solvates racemic mixtures, enantiomers, diasteromers, and tautomers thereof, wherein A, R.sub.1, R.sub.2, R.sub.3, R.sub.3′, R.sub.4, R.sub.4′, R.sub.5, R.sub.6, R.sub.7, R.sub.8, m, and n are as defined in the detailed description.
##STR00001##
Pyrene-triazine derivative and applications thereof in organic electronic component
A pyrene-triazine compound, a mixture containing same, a formulation, an organic electronic component, and applications. The pyrene-triazine compound comprises a triazine structure of three strong electron affinity nitrogen atoms and a pyrene fused ring structure. Because the triazine structure has great optoelectronic performance and a planar structured pyrene derivative has great carrier transport performance and optoelectronic performance, the application of the pyrene-triazine compound in the organic electronic component produces a light-emitting component having high efficiency and an extended service life.